The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 701–800 of 1,002
Nayak, S. S., Amini‐Salehi, E., Joukar, F., Biswas, P., Nobakht, S., Letafatkar, N., Porteghali, P., Mohammadi‐Vajari, E., Mansour‐Ghanaei, F., Javid, M., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002048 · Cited by 20
“Left untreated, it signi fi cantly ampli fi es susceptibility to cardiovascular, metabolic, and renal ailments compared to alternative hypertension etiologies such as electrolyte imbalance and volume expansion [5,10,45 – 51] .”
InfluentialAnanda, R. A., Gwini, S. M., Beilin, L. J., Schlaich, M. P., Stowasser, M., Young, M. J., Adler, B. D., Fuller, P. J., Mori, T. A., & Yang, J. (2024) · Circulation · doi:10.1161/circulationaha.124.070039 · Cited by 21
Self-citationNationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program
Brown, J. M., Tsai, L. C., Abel, E. E., Ferrebus, A., Moore, A. E., Niebuhr, Y., Bacare, B., Honzel, B., Milks, J., Foote, K., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.24648 · Cited by 20
Evaluation of Cortisol Production in Aldosterone-Producing Adenoma
Inoue, K., Yamazaki, Y., Tsurutani, Y., Suematsu, S., Sugisawa, C., Saito, J., Omura, M., Sasano, H., & Nishikawa, T. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119878 · Cited by 19
“PRA can be lower than PAC, which results in elevated ARR for patients who are ≥ 65 years [1], and oestrogens and progesterones might affect the renin-angiotensin-aldosterone system [31].”
BackgroundProgress in the Management of Primary Aldosteronism
Morimoto, R., Omata, K., Ito, S., & Satoh, F. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy018 · Cited by 18
Primary aldosteronism in the primary care setting
Buffolo, F., Monticone, S., Tetti, M., & Mulatero, P. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000408 · Cited by 22
Jia, W. P., Li, S., Liu, Q., Zhu, Y., Wu, N., Tang, Y., Li, Q., Ren, K., Zhang, Q., Yu, Y., et al. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0250-6 · Cited by 37
Advances in adrenal tumors 2018
Crona, J., Beuschlein, F., Pacák, K., & Skogseid, B. M. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0138 · Cited by 21
Sabbadin, C., Ceccato, F., Ragazzi, E., Boscaro, M., Betterle, C., & Armanini, D. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13351 · Cited by 18
“Age (y) 55 (15) 55 (12) 58 (14) 51 (13) NS”
Rossi, G. P., Mulatero, P., & Satoh, F. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001939 · Cited by 19
Primary aldosteronism: Treatment of the disease, and new therapeutic approaches
Funder, J. W. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101368 · Cited by 20
Self-citationSung, T., Alobuia, W. M., Tyagi, M. V., Ghosh, C., & Kebebew, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051447 · Cited by 18
“3%–10% of general hypertensive patients [1,2] and up to 20% of patients with resistant hypertension [3].”
BackgroundMethodInfluentialChan, C., Yang, W., Lin, Y., Huang, K., Lu, C., Hu, Y., Wu, V., Chueh, S., Chu, T., & Chen, Y. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa566 · Cited by 20
Nakamura, Y., Kobayashi, H. H., Tanaka, S., Hatanaka, Y., Fukuda, N., & Abe, M. (2021) · Clinical Endocrinology · doi:10.1111/cen.14434 · Cited by 18
Gendreitzig, P., Kunzel, H. E., Adolf, C., Handgriff, L., Müller, L., Holler, F., Sturm, L., Heinrich, D. A., Reincke, M., & Quinkler, M. O. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab099 · Cited by 18
“For inclusion in the registry, patients had to meet the diagnostic criteria for PA, as stated in the guidelines of the Endocrine Society (30).”
MethodSelf-citationYang, Y., Tetti, M., Vohra, T., Adolf, C., Seißler, J., Hristov, M., Belavgeni, A., Bidlingmaier, M., Linkermann, A., Mulatero, P., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16774 · Cited by 19
Self-citationCano-Valderrama, Ó., González-Nieto, J., Abad-Cardiel, M., Cámara, S. O., Rünkle, I., Mendez, J., García‐Donaire, J. A., Cuesta-Hernández, M., Armijo, J., de Miguel-Novoa, P., et al. (2021) · Surgical Endoscopy · doi:10.1007/s00464-021-08481-3 · Cited by 18
“Those patients with an unsuccessful AVS due to anatomical abnormalities or who did not undergo AVS were evaluated with SPECT/TC scintigraphy and/or TC according to published guidelines [5].”
BackgroundMethodInfluentialConcomitant Pheochromocytoma and Primary Aldosteronism: A Case Series and Literature Review
Mao, J. J. M., Baker, J. E., Rainey, W. E., Young, W. F., & Bancos, I. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab107 · Cited by 19
“A positive confirmatory test for PA was defined by a 24-hour urinary aldosterone excretion >12 mcg after oral sodium loading [19].”
MethodSelf-citationFuß, C. T., Brohm, K., Faßnacht, M., Kroiß, M., & Hahner, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab611 · Cited by 19
Sousa, K. D., Abdellatif, A. B., Giscos-Douriez, I., Méatchi, T., Amar, L., Fernandes-Rosa, F. L., Boulkroun, S., & Zennaro, M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab707 · Cited by 19
Bollati, M., Lopez, C., Bioletto, F., Ponzetto, F., Ghigo, E., Maccario, M., & Parasiliti‐Caprino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042111 · Cited by 21
“Laparoscopic adrenalectomy is the treatment of choice in unilateral PA, whereas medical treatment with mineralocorticoid receptor (MR) antagonists (MRAs) represents the preferred option in bilateral forms [1,2].”
BackgroundMansur, A., Vaidya, A., & Turchin, A. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad032 · Cited by 19
Fully automated chemiluminescence vs RIA aldosterone assay in primary aldosteronism work-up
Pizzolo, F., Salvagno, G. L., Caruso, B., Cocco, C., Zorzi, F., Zaltron, C., Castagna, A., Bertolone, L., Morandini, F., Lippi, G., et al. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.62 · Cited by 18
Bone Health in Adrenal Disorders
Kim, B., Lee, S. H., & Koh, J. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.1.1 · Cited by 20
Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
“Primary aldosteronism (15) Endocrine Society 2016 8 3 Yes 3 0 0 0 0 50 Bone Osteoporosis in men (16) Endocrine Society 2013 7 6 Yes 6 M 5 5 685 918 Paget disease (17) Endocrine Society 2014 7 5 No 5 M 4 2 308 367 Vitamin D deficiency (18) Endocrine Society 2011 8 3 Yes 2 M 1 0 202 217 Diabetes Diabetes and pregnancy (…”
BackgroundKietsiriroje, N., Wonghirundecha, R., Suntornlohanakul, O., & Murray, R. D. (2019) · Clinical Endocrinology · doi:10.1111/cen.14142 · Cited by 19
Sawamura, T., Karashima, S., Nagase, S., Nambo, H., Shimizu, E., Higashitani, T., Aono, D., Ohbatake, A., Kometani, M., Demura, M., et al. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00656-8 · Cited by 18
Somatic GNAQ , CTNNB1 , and CACNA1C Mutations in Cat Aldosterone-Secreting Tumors
Watson, A. H., Syme, H. M., & Mj, B. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.23501 · Cited by 19
Treatment of Unilateral PA by Adrenalectomy: Potential Reasons for Incomplete Biochemical Cure
Yang, Y., Reincke, M., & Williams, T. A. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0662-6081 · Cited by 19
“Functional molecular imaging approaches using the CXCR4 ligand 68Ga-pentixafor may visualise the hypersecreting adrenal [75] as well as other functional imaging methods such as 11C-metomidate positron emission tomography-CT imaging and (6β-131I) iodomethyl-19-norcholesterol scan [14].”
InfluentialSelf-citationPrimary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation
Nguyen, V. A. T., Tu, T. M., Mamauag, M. J., Lai, J., Saffari, S. E., Aw, T. C., Ong, L., Foo, R., Chai, S. C., Fones, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.869980 · Cited by 19
Xu, W., Dong, J., Ji, R., Liu, G., Zhou, J., 王惠珍, Ji, Z., & Cui, L. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2023.1071321 · Cited by 18
Ruiz-Sánchez, J. G., Paja-Fano, M., Boillos, M. G., Peris, B. P., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Delgado, A. V., Hoyos, E. G., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad400 · Cited by 18
Role of Adrenal Vein Sampling in Guiding Surgical Decision in Primary Aldosteronism
Younès, N., Larose, S., Bourdeau, I., Thérasse, É., & Lacroix, A. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2106-4663 · Cited by 17
Endocrine causes of hypertension: literature review and practical approach
de Fréminville, J.-B., Amar, L., Azizi, M., & Mallart-Riancho, J. (2023) · Hypertension Research · doi:10.1038/s41440-023-01461-1 · Cited by 18
“Adrenal vein sampling (AVS) is considered by a large number of authors as the gold standard exam to con fi rm unilateral secretion of aldosterone and is recommended by all guidelines [60 – 62].”
MethodLiu, X., Hao, S., Bian, J., Lou, Y., Zhang, H., Wu, H., Cai, J., & Ma, W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae094 · Cited by 17
Pintus, G., Seccia, T. M., Amar, L., Azizi, M., Riester, A., Reincke, M., Widimsky, J., Jr., Naruse, M., Kocjan, T., Negro, A., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22721 · Cited by 17
Self-citationTemporal trends in clinical features of patients with primary aldosteronism over 20 years
Park, S. S., Ahn, C. H., Kim, S. W., Koh, J., Lee, S. H., & Kim, J. H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01703-w · Cited by 17
“We diagnosed PA in the case of PAC > 10 ng/dL after the saline infusion test in a recumbent position [1].”
BackgroundMethodInfluentialSakizlian, D. D. M., Boldeanu, L., Mitrea, A., Clenciu, D., Vladu, I. M., Plasiciuc, A. E. C., Șarla, A. V., Siloşi, I., Boldeanu, M. V., Assani, M.-Z., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136227 · Cited by 18
“The elevated prevalence of alcohol consumption and tobacco use within this demographic corresponds with lifestyle behaviors that are recognized to intensify oxidative stress and the inflammatory processes implicated in the advancement of MetS [38].”
Luo, Q., Li, N., Wang, M., Yao, X., Heizhati, M., Zhang, D., Zhou, K., Wang, G., Hu, J., & Zhu, B. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0291-y · Cited by 18
Prospective evaluation of aldosterone LC-MS/MS-specific cutoffs for the saline infusion test
Fries, C., Bae, Y. J., Rayes, N., Sandner, B., Isermann, B., Stümvoll, M., Fagotto, V., Reincke, M., Bidlingmaier, M., Mandy, V., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0030 · Cited by 20
Self-citationMa, D., Liu, X., Zeng, L., Yuan, P., Liu, Z., Xie, J., Yuan, G., Wang, S., Yu, X., Yang, Y., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002634 · Cited by 17
“Meanwhile, it should also be noted that improvement of hypertension post adrenalectomy is related to the age and duration of hypertension, and patients with older age or longer duration of hypertension have been reported to have a higher risk of persistently increased BP after adrenalectomy [4].”
BackgroundInfluentialParksook, W. W., Yozamp, N. S., Hundemer, G. L., Moussa, M., Underhill, J., Fudim, T., Sacks, B. A., & Vaidya, A. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab189 · Cited by 19
Chen, P., Chang, D., Liu, K., Liao, W., Wang, W., Chang, C., Wu, V., & Lin, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-12835-9 · Cited by 18
Chang, C., Hu, Y.-H., Tsai, Y., Wu, C., Wang, S., Lin, L., Lin, Y., Satoh, F., Wu, K., & Wu, V. (2017) · Oncotarget · doi:10.18632/oncotarget.16269 · Cited by 18
Spironolactone in cardiovascular disease: an expanding universe?
Funder, J. W. (2017) · F1000Research · doi:10.12688/f1000research.11887.1 · Cited by 18
Self-citationPrevalence of Somatic KCNJ5 Mutations in Thai Patients With Aldosterone-Producing Adrenal Adenomas
Parksook, W. W., Atikankul, T., Houngngam, N., & Sunthornyothin, S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00097 · Cited by 18
“The diagnostic process of APA was formulated according to the recommendations of the current guidelines [11].”
MethodPrimary Aldosteronism: Present and Future
Funder, J. W. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.10.006 · Cited by 19
Self-citationCampbell, R. A., Young, D. S., Shaver, C. N., Snyder, S. M., Milan, S. A., Lairmore, T. C., & McDonald, D. K. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.03.012 · Cited by 18
Chan, C., Kim, J. H., Chueh, E., Chang, C., Lin, Y., Lai, T., Huang, K., Lin, Y., & Wu, V. (2019) · Surgery · doi:10.1016/j.surg.2019.05.001 · Cited by 18
CaF2 nanoparticles as peroxidase mimics for rapid and sensitive detection of aldosterone
Fu, B., Liu, T., Chen, J., & Li, K. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.06.005 · Cited by 17
Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management
Pillai, P. R., Griffith, M. P., Schwarcz, M., & Weiss, I. A. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000281 · Cited by 19
“Options include surgical resection of an adenoma, medical management to decrease aldosterone secretion, or glucocorticoids in the case of FH.(20,59) Patients with PA should be treated with either unilateral adrenalectomy or MRAs.”
InfluentialManagement of primary aldosteronism and mineralocorticoid receptor-associated hypertension
Morimoto, S., & Ichihara, A. (2020) · Hypertension Research · doi:10.1038/s41440-020-0468-3 · Cited by 18
Zhang, Z., Luo, Q., Tuersun, T., Wang, G., Wu, T., Zhang, D., Wang, M., Zhou, K., Sun, L., Yue, N., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14318 · Cited by 17
“Duration of hypertension (years) 3 (1-9) 6.”
Donlon, P. T., Fallahi, H., Beard, W. L., Shahzad, A., Heflin, L., Cox, W., Bloomberg, B., Lillich, J. D., Ganta, C. K., O’Sullivan, G. J., et al. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1650205 · Cited by 17
“in order to avoid post-therapy hormonal deficiency [6,22,23].”
BackgroundWho and How Should We Screen for Primary Aldosteronism?
Funder, J. W. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20536 · Cited by 17
Self-citationUnanswered Questions in the Genetic Basis of Primary Aldosteronism
Scholl, U. I. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-120066 · Cited by 16
“It is expected that genetic studies over the next few years will lead to answers to at least some of the questions raised. centers is about 6–10 % [2–4].”
InfluentialAldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension
Gray, Z., Tu, W., Chertow, G. M., & Bhalla, V. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00415.2020 · Cited by 18
“The implications of demonstrating and accounting for changes in blood pressure sensitivity to aldosterone would fundamentally alter how we currently interpret plasma aldosterone for the diagnosis of Conn’s syndrome or syndromes of apparent mineralocorticoid excess (84).”
BackgroundHe, Z., Chen, S., Lü, M., Luo, Y., Liu, T., Xiao, Y., & Wang, X. (2021) · Updates in Surgery · doi:10.1007/s13304-021-01188-z · Cited by 17
Kantauskaitė, M., Bolten, K., Boschheidgen, M., Schmidt, C., Kolb, T., Eckardt, K., Pasch, A., Schimmöller, L., Rump, L. C., Voelkl, J. G. J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.771096 · Cited by 16
Standard −20 °C freezer storage protocols may cause substantial plasma renin cryoactivation
Bonnitcha, P., Rigdwell, M., Ward, P., & Chesher, D. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1190 · Cited by 16
Yin, Y., Ma, C., Yu, S., Ai, Q., Han, C., Zhong, J., Luo, W., Ma, X., Yu, J., Zhang, Y., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117325 · Cited by 16
Marzano, L. A., Kazory, A., Husain‐Syed, F., & Ronco, C. (2023) · Clinical Endocrinology · doi:10.1111/cen.14918 · Cited by 16
“Moreover, in comparison with age‐, sex‐, BP‐ matched patients with essential hypertension, those with primary aldosteronism are at particularly higher risk of cardiovascular and renal complications, including atrial fibrillation, myocardial infarction, strokes, chronic kidney disease and death.(6,9) Therefore, early i…”
ResultHong, N., Kim, K. J., Yu, M. H., Jeong, S. H., Lee, S., Lim, J. S., & Rhee, Y. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01274-x · Cited by 16
“Primary aldosteronism (PA) is the most common cause of secondary hypertension that is characterized by excessive autonomous aldosterone production [1].”
BackgroundMarzano, L. A., & Ronco, C. (2024) · Hypertension Research · doi:10.1038/s41440-023-01554-x · Cited by 18
“Numerous clinical, laboratory, and genetic factors that predict CCS after adrenalectomy in unilateral primary aldosteronism have been investigated and evaluated, often with con fl icting results [1, 14, 18, 30, 31].”
Okubo, J., Frudit, P., Cavalcante, A. C. B. S., Maciel, A. A. W., Freitas, T. C., Pilan, B., Fagundes, G. F. C., Queiroz, N. L., Stumpf, M. A. M., Souza, V. C. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae142 · Cited by 16
Approach to the Patient With Bilateral Adrenal Masses
Vassiliadi, D. A., Delivanis, D. A., Papalou, O., & Tsagarakis, S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae164 · Cited by 16
Yi, T., Lu, D., Cui, Y., Zhang, Z., Yang, X., Zhang, J., Qiu, L., Weng, H., Liu, L., Duan, X., et al. (2024) · Molecular Imaging and Biology · doi:10.1007/s11307-024-01976-0 · Cited by 17
“The diagnostic criteria of PA were based on the clinical guidelines subcommittee of the Endocrine Society as followings [2]: (1) persistent hypertension with blood pressure > 160/100mmHg and/or hypokalemia; (2) aldosterone-to-renin ratio (ARR) > 3.7 (ng/dL)/(mU/L); (3) a positive captopril…”
InfluentialHuang, C. L., Chang, L., Sheu, J.-Y., Huang, Y., Chen, J., Lai, C., & Wu, V. (2025) · Hypertension Research · doi:10.1038/s41440-025-02172-5 · Cited by 19
Improved and individualized approach to adrenal surgery
Carling, T., & LaRue, M. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0296 · Cited by 17
Obesity and the diagnostic accuracy for primary aldosteronism
Tirosh, A., Hannah‐Shmouni, F., Lyssikatos, C., Belyavskaya, E., Zilbermint, M. F., Abraham, S. B., Lodish, M. B., & Stratakis, C. A. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13041 · Cited by 17
Role of Venous Sampling in the Diagnosis of Endocrine Disorders
England, R. W., Geer, E. B., & Deipolyi, A. R. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7050114 · Cited by 18
“Patients younger than 35 years with hypokalemia, marked hyperaldosteronemia, and unilateral adrenal lesions with imaging consistent with a cortical adenoma on CT scan may also not need AVS before proceeding to adrenalectomy [25,29].”
BackgroundPostmenopausal osteoporosis is associated with elevated aldosterone/renin ratio
the Chongqing Primary Aldosteronism Study(CONPASS) Group, Shu, X., Mei, M., Ma, L., Wang, Z., Yang, S., Hu, J., Song, Y., He, W., Luo, T., et al. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0069-7 · Cited by 19
“should be started [11], so a large number of postmenopausal”
BackgroundThe Differential Effect of Excess Aldosterone on Skeletal Muscle Mass by Sex
Kwak, M. K., Lee, S., Cho, Y. Y., Suh, S., Kim, B., Song, K., Koh, J., Kim, J. H., & Lee, S. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00195 · Cited by 17
“Before measuring the PAC (ng/dL) and plasma renin activity (PRA, ng/mL/h) to detect possible case of PA [determined by calculating the aldosterone to renin ratio (ARR)], all antihypertensive medications, such as angiotensin II receptor blockers ACE inhibitors, were withdrawn for ≥4 weeks to prevent possible interferen…”
BackgroundMethodInfluentialMarkers of Subclinical Cardiovascular Disease in Patients with Adrenal Incidentaloma
Szychlińska, M., Baranowska-Jurkun, A., Matuszewski, W., Wołos-Kłosowicz, K., & Bandurska-Stankiewicz, E. M. (2020) · Medicina · doi:10.3390/medicina56020069 · Cited by 18
Lim, Y. Y., Libianto, R., Shen, J., Young, M. J., Fuller, P. J., & Yang, J. (2021) · Internal Medicine Journal · doi:10.1111/imj.14879 · Cited by 16
Zhang, Y., Luo, F., Fan, P. T., Meng, X., Yang, K., & Zhou, X. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00601-9 · Cited by 16
Effect of renal denervation on catecholamines and the renin–angiotensin–aldosterone system
Feyz, L., van den Berg, S. A. A., Zietse, R., Kardys, I., Versmissen, J., & Daemen, J. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320943095 · Cited by 16
Zhou, F., Wu, T., Wang, W., Cheng, W., Wan, S., Tian, H., Chen, T., Sun, J., & Ren, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672557 · Cited by 16
Wu, T., Ren, Y., Wang, W., Cheng, W., Zhou, F., He, S., Liu, X., Li, L., Tang, L., Deng, Q., et al. (2021) · Korean Journal of Radiology · doi:10.3348/kjr.2020.1291 · Cited by 17
“…trial showed that mineralocorticoid receptor antagonists (MRAs) may have a beneficial effect in the early stages of heart failure [41], implying that excessive exposure to aldosterone may lead to ventricular remodeling in patients with PA. MRAs are also recommended in the 2016 guidelines [2].”
Multiple endocrine neoplasia 1: a broad overview
Thompson, R. L., & Landry, C. S. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211035288 · Cited by 19
Transcriptomics, Epigenetics, and Metabolomics of Primary Aldosteronism
Spyroglou, A., Piaditis, G. P., Kaltsas, G., & Alexandraki, K. (2021) · Cancers · doi:10.3390/cancers13215582 · Cited by 21
“Primary aldosteronism (PA) is the most common cause of endocrine hypertension, with a prevalence of approximately 10% in hypertensive subjects [1,2].”
BackgroundRecent Advances in the Clinical Application of Adrenal Vein Sampling
Zhong, S., Zhang, T., He, M., Yu, H., Liu, Z., Li, Z., Song, X., & Xu, X. N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.797021 · Cited by 16
Pathophysiology of bilateral hyperaldosteronism
Nanba, K., & Rainey, W. E. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000729 · Cited by 16
Histopathologic Features of Adrenal Cortical Carcinoma
Gambella, A., Volante, M., & Papotti, M. G. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000363 · Cited by 20
Who should be screened for primary aldosteronism? A comprehensive review of current evidence
Huang, W., Lin, Y., Wu, V., Chen, C., Siddique, S., Chia, Y. C., Tay, J. C., Guruprasad, S., Cheng, H., & Kario, K. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14558 · Cited by 18
Yang, J., Gwini, S. M., Beilin, L. J., Schlaich, M. P., Stowasser, M., Young, M. J., Fuller, P. J., & Mori, T. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad010 · Cited by 18
Self-citationInvestigation and assessment of adrenal incidentalomas
Cuthbertson, D. J., Alam, U., Davison, A., Belfield, J. C., Shore, S., & Vinjamuri, S. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0042 · Cited by 20
Ouyang, J., Hardy, R., Brown, M. J., Helliwell, T. R., Gurnell, M., & Cuthbertson, D. J. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.9 · Cited by 16
New Advances in the Diagnostic Workup of Primary Aldosteronism
Wolley, M. J., & Stowasser, M. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1107 · Cited by 20
Self-citationBao, M., Cai, J., Yang, X., & Ma, W. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1489547 · Cited by 16
“Of the 136 patients, 22 were clinically suspected to have primary aldosteronism and presented with good therapeutic responses to standard medication or surgical treatment (15).”
BackgroundAdrenocortical incidentalomas and bone: from molecular insights to clinical perspectives
Altieri, B., Muscogiuri, G., Paschou, S. Α., Vryonidou, A., Casa, S. D., Pontecorvi, A., Faßnacht, M., Ronchi, C. L., & Newell-Price, J. D. C. (2018) · Endocrine · doi:10.1007/s12020-018-1696-z · Cited by 17
Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Stavropoulos, K., Papadopoulos, C. E., Koutsampasopoulos, K., Lales, G., Mitas, C., & Doumas, M. N. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190311130138 · Cited by 16
Shariq, O. A., Mehta, K., Thompson, G. B., Lyden, M. L., Farley, D. R., Bancos, I., Dy, B. M., Young, W. F., & McKenzie, T. J. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05059-y · Cited by 17
Self-citationWang, D., Xu, J., Chen, X., Xu, T., Zhang, W., Li, Y., & Wang, J. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002146 · Cited by 16
“A physiological saline infusion test was then performed to confirm the diagnosis of primary aldosteronism, with a cut-off value of at least 100 pg/ml of plasma aldosterone concentration [19].”
MethodThe characteristics of captopril challenge test–positive patients using various criteria
Kidoguchi, S., Sugano, N., Hayashi-Ishikawa, N., Morisawa, N., Tokudome, G., & Yokoo, T. (2019) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320319870891 · Cited by 16
Lin, C., Yang, J., Fuller, P. J., Jing, H., Song, Y., He, W., Du, Z., Luo, T., Cheng, Q., Yang, S., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14134 · Cited by 16
“Duration of HT (years) 3 (1,8) 5 (2,10) .”
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 18
Significance of Discordant Results Between Confirmatory Tests in Diagnosis of Primary Aldosteronism
Fukumoto, T., Umakoshi, H., Ogata, M., Yokomoto‐Umakoshi, M., Matsuda, Y., Motoya, M., Nagata, H., Nakano, Y., Iwahashi, N., Kaneko, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa812 · Cited by 18
Veldhuizen, G. P., Alnazer, R. M., Kroon, A. A., & de Leeuw, P. W. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14117 · Cited by 18
“remaining articles were read in full and considered eligible if they (1) had a clearly described and reproducible method for the determination of renin and aldosterone and (2) clearly described the type of participants that were investigated, for example, patients referred for evaluation of treatment-resistant hyperte…”
MethodGrams, M. E., Hoenig, M. P., & Hoorn, E. J. (2021) · JAMA · doi:10.1001/jama.2020.17672 · Cited by 16
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.